Insulin glargine (Lantus®)

International Journal of Clinical Practice

Volumn 56, Issue 6, 2002, Pages 460-466

  Owens, D R ^a   Griffiths, S ^a  

^a LLANDOUGH HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; INSULIN; INSULIN DERIVATIVE; INSULIN GLARGINE; INSULIN ZINC SUSPENSION; ISOPHANE INSULIN; ORAL ANTIDIABETIC AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; CARCINOGENESIS; CONTROLLED STUDY; DIET RESTRICTION; DIET THERAPY; DOSE CALCULATION; DRUG ABSORPTION; DRUG ACCUMULATION; DRUG EFFICACY; DRUG METABOLISM; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; EXERCISE; GLUCOSE BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; INDIVIDUALIZATION; INSULIN DEPENDENT DIABETES MELLITUS; NIGHT; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PATIENT SATISFACTION; PRIORITY JOURNAL; RAT; REVIEW; RISK ASSESSMENT; TREATMENT FAILURE;

ADULT; AGED; BLOOD GLUCOSE; DELAYED-ACTION PREPARATIONS; DIABETES MELLITUS; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; HUMANS; INSULIN; MIDDLE AGED;

EID: 0036332546     PISSN: 13685031     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (63)

1. Control of glycaemia
2. Autoregulation of hepatic glucose production
3. Insulins today and beyond
4. Regulation of hepatic glucose production in healthy subjects and patients with non-insulin dependent diabetes mellitus
5. Sulfonylureas in NIDDM
6. Early metabolic defects in persons at increased risk for non-insulin-dependent diabetes mellitus
7. Global burden of diabetes, 1995-2025: Prevalence, numerical estimates, and projections
8. Diabetes
9. Emerging epidemic of type 2 diabetes in youth
10. Epidemiology of severe hypoglycemia in the Diabetes Control and Complications Trial
11. From insulin to insulin analogs: Progress in the treatment of type 1 diabetes
12. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: A randomized prospective 6-year study
13. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): Prospective observational study
14. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)
15. The effect of intensive treatment of diabetes on the development and progression of longterm complications in insulin-dependent diabetes mellitus
16. Lifetime benefits and costs of intensive therapy as practiced in the diabetes control and complications trial
17. Basal insulin therapy in type 2 diabetes: 28-week comparison of insulin glargine (HOE 901) and NPH insulin
18. Definition, diagnosis and classification of diabetes mellitus and its complications part 1: Diagnosis and classification of diabetes mellitus provisional report of a WHO consultation
19. The pharmacological treatment of hyperglycemia in NIDDM
20. Glimepiride: Role of a new sulfonylurea in the treatment of type 2 diabetes mellitus
21. Current therapies and emerging targets for the treatment of diabetes
22. Long-acting insulin analogs
23. Nocturnal blood glucose control in type 1 diabetes mellitus
24. Nocturnal hypoglycaemia in patients with insulin-dependent diabetes mellitus
25. An assessment of the variability in the pharmacodynamics (glucose lowering effect) of HOE901 compared to NPH and ultralente human insulins using the euglycaemic clamp technique
26. Absorption of isophane (NPH) insulin and its clinical implications
27. Insulin analogs with improved pharmacokinetic profiles
28. Time-action profile of the long-acting insulin analog insulin glargine (HOE901) in comparison with those of NPH insulin and placebo
29. Insulin glargine
30. Insulin analogues and their potential in the management of diabetes mellitus
31. Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro
32. Insulin glargine: The first clinically useful extended-acting insulin in half a century?
33. Pharmacokinetics of [125]I- labelled insulin glargine (HOE 901) in healthy men
34. Comparison of the subcutaneous absorption of HOE 901 and NPH human insulin in pat type 2 diabetic subjects
35. No evidence for accumulation of HOE901 after multiple injections in type 1 diabetic patients
36. Kinetics and metabolite profile of insulin glargine (Lantus®)
37. Physiological responses during hypoglycaemia induced by regular human insulin or a novel human analogue, insulin glargine
38. HOE901: A new insulin with prolonged action
39. Less hypoglycemia with insulin glargine in intensive insulin therapy for type 1 diabetes
40. A 16-week comparison of the novel insulin analog insulin glargine (HOE 901) and NPH human insulin used with insulin Lispro in patients with type 1 diabetes
41. Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes
42. Efficacy and safety of HOE901 versus NPH insulin in patients with type 1 diabetes
43. Basal insulin glargine (HOE 901) versus NPH insulin in patients with type 1 diabetes on multiple daily insulin regimens. US Insulin Glargine (HOE 901) type 1 Diabetes Investigator Group
44. Beneficial effects of insulin glargine compared to NPH in subjects with type 1 diabetes
45. Comparison of insulin glargine (HOE 901) and NPH-insulin in intensified therapy of type-1 diabetics: Results of an international, multicenter, randomized 28-week study
46. Comparative trial between insulin glargine and NPH insulin in children and adolescents with type 1 diabetes
47. Nocturnal glucose control and free insulin levels in children with type 1 diabetes by use of the long-acting insulin HOE 901 as part of a three-injection regimen
48. Treatment satisfaction and psychological well-being with insulin glargine compared with NPH in patients with type 1 diabetes
49. Comparison of insulin glargine (HOE 901) and NPH insulin in combination with oral antidiabetics for treatment of type 2 diabetic patients: Results of an international multicentre, randomized 1-year study
50. The Multicentre HOE901 Research Group. Less nocturnal hypoglycaemia with insulin glargine versus NPH insulin in patients with type 2 diabetes receiving combination therapy
51. Less symptomatic hypoglycaemia with insulin glargine compared to NPH insulin in patients with type 2 diabetes
52. Treatment to target study: Feasibility of achieving control with the addition of basal bedtime insulin glargine (Lantus) or NPH insulin in insulin-naive patients with type 2 diabetes on oral agents
53. Improved psychological outcomes after initiation of insulin treatment in patients with type II diabetes
54. Sustained signalling from the insulin receptor after stimulation with insulin analogues exhibiting increased mitogenic potency
55. Carcinogenic effect of the human insulin analogue B10Asp in female rats
56. The long-acting human insulin analog HOE901: Characteristics of insulin signalling in comparison to Asp(B10) and regular insulin
57. Growth promoting and metabolic activity of the human insulin analogue [GlyA21, ArgB31, ArgB32] insulin (HOE 901) in muscle cells
58. Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use
59. Effects of the long acting insulin analog insulin glargine on cultured human skeletal muscle cells: Comparisons to insulin and IGF-1
60. Insulin glargine is not carcinogenic in rats and mice
61. Cotherapy with recombinant human insulin-like growth factor I and insulin improves glycemic control in type 1 diabetes
62. Progression of retinopathy with insulin glargine or NPH insulin: A multi-trial analysis
63. Why some cases of retinopathy worsen when diabetic control improves